Helixgate https://validator.w3.org/feed/docs/rss2.html Microbial Dark Matter Could Revive Antibiotics Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors Crossing the Digital Validation Chasm How the Heart Stays Strong with MCT1-Dependent Mitochondrial Lactate Import Three-Photon Microscopy Reveals Neural Activity Deep in the Mouse Brain Hamburg Hosts 2026 European Gene Therapy Conference Building the Future of AAV Gene Therapy Brain Quality Control Selectively Eliminates Neurons with Abnormal Variants in Development Stability, speed and strategy: Inside Australia’s early‑stage edge Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat Dren Bio lands $350M to push rare blood cancer therapy toward market Quality and Regulatory Predictability: Shaping USP Standards – 12/11/2025 Search for Regulatory References | Drugs FDA Drug Info Rounds Video Frequently Requested or Proactively Posted Compliance Records Submit an eCTD v4.0 or Standardized Data Sample to the FDA Project Orbis Webinar for Stakeholder Engagement on the New Final Guideline on General Principles for Model-Informed Drug Development (ICH M15) – 10/29/2026 Drugs@FDA Data Files Newly Added Guidance Documents What’s New Related to Drugs eCTD Submission Standards for eCTD v4.0 and Regional M1 STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more STAT+: HHS moves to allow compounding of some unapproved peptides Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout AbbVie bids to join the BCMA crowd with etentamig GSK shares come under pressure from weaker vaccine sales Artiva to quit autoimmune cell therapy work, cut staff after patient deaths Ferring to acquire next-gen IVF startup Gameto for up to $1.4B FDA unveils guidance for ‘plug and play’ gene therapies Oruka raises efficacy expectations for long-acting IL-23 inhibitors PACE panels tackle challenges to access and barriers to coverage Behind the scenes of 3 Big Pharma layoffs Biotechs going to market alone must learn to go global Big Pharma is ready to strike, with J&J most likely to buy: Leerink Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025 Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss New FDA draft guidance doubles down on expediting approvals of personalized gene therapies Biogen set up for growth even without M&A but CEO won’t rule it out Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout An engineered, compact Cas12m variant for multiplexed gene activation in vivo An mRNA–lipid nanoparticle vaccine against H5N1 influenza virus protects lactating dairy cows from infection Novartis Remibrutinib Delivered Comprehensive Disease Control in Phase III RMS Trials, with Proven, Robust Safety Profile Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study Sonesitatug Vedotin Reduced the Risk of Death by 42% in 2nd- and Later-Line CLDN18.2-Positive Advanced Gastric/GEJ Cancers in CLARITY-Gastric01 Pfizer’s 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus Home